Thalia Therapeutics

Annual Report - 2021

Interim Results - 2021

Attendance at AGM - 2021

Notice of AGM - 2021

Proxy Card - 2021

Admission document

Articles of Association

Annual Report - 2023

Interim Results - 2023

Notice of AGM -  2023

Proxy Card - 2023

Notice of GM 2026

Proxy Card - 2026

Corporate Governance Statement

Notice of AGM - 2025

Annual Report - 2025

Proxy Card - 2025

Interim Results - 2025

Notice of AGM - 2024

Proxy Card - 2024

Interim Results -  2024

Annual Report - 2022

Interim Results - 2022

Notice of AGM  -  2022

Proxy Card - 2022

2020 Annual Report

2019 Annual Report

2018 Annual Report

2017 Annual Report

2016 Annual Report

2015 Annual Report

2014 Annual Report

AIM Rule 26

Default features description for sign up page.

Regulatory news

Home

Media

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Number of AIM securities in issue – 832,280,349 (as at 23 February 2026) ordinary shares of 0.4p. No Ordinary Shares are held in treasury.

*Percentage of AIM Securities not in public hands - 20.09% (as at 23 May 2025) the company had previously included nominee account shareholdings in the table above and in the calculation for "shares not in public hands." Having completed an analysis of the underlying beneficial shareholders to the nominee holdings, the company has identified that there are no notifiable interests pursuant to AIM Rule 26 save for as included in the table above.

Investor documents available for download.

The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies and was last updated on 23 February 2026. N4 Pharma plc (to be renamed Thalia Therapeutics plc, subject to shareholder approval) is incorporated in England (Registration Number 01435584). The Company’s principal country of operation is the United Kingdom.

N4 Pharma (to be renamed Thalia Therapeutics, subject to shareholder approval) is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare. Find out more about what we do here.

Established in 2014 and floated on the AIM stock market in May 2017. The Company is not listed on any other exchanges or platforms.

There are no restrictions on the transfer of AIM securities.

The Company is subject to the City Code Takeovers and Mergers

The N4 Pharma board has a proven track record at a senior level in major international pharmaceutical companies and extensive experience of start-ups in the pharmaceutical and biotech field.

It is the Board’s job to ensure that N4 Pharma Plc is managed for the long-term benefit of all shareholders, with effective and efficient decision-making. Corporate governance is an important part of that job, reducing risk and adding value to our business.


Statement of Compliance with the QCA Corporate Governance Code below

. This statement will be updated annually at the time of publication of the annual report and accounts. The statement was last updated on 03 December 2024.